Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anastasios Lymperopoulos

Showing results (21-30 of 107) with videos related to

Pageof 11
Sort By:
Pharmacogenomics|December 11, 2014
Pharmacogenetics of cardiac inotropyAnastasios Lymperopoulos, Dilayda Garcia, Karlee Walklett
World Journal of Cardiology|September 29, 2015
Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failureKatie A McCrink, Ava Brill, Anastasios Lymperopoulos
Pharmacology Research & Perspectives|June 26, 2019
Adrenal βarrestin1 targeting for tobacco-associated cardiac dysfunction treatment: Aldosterone production as the mechanistic linkMaria E Solesio, Erna Mitaishvili, Anastasios Lymperopoulos
Circulation Research|August 31, 2013
Adrenergic nervous system in heart failure: pathophysiology and therapyAnastasios Lymperopoulos, Giuseppe Rengo, Walter J Koch
Current Pharmaceutical Design|January 11, 2012
GRK2 inhibition in heart failure: something old, something newAnastasios Lymperopoulos, Giuseppe Rengo, Walter J Koch
Current Drug Metabolism|November 6, 2015
Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and MetoprololAnastasios Lymperopoulos, Katie A McCrink, Ava Brill
The International Journal of Biochemistry & Cell Biology|February 7, 2016
GPCRs of adrenal chromaffin cells & catecholamines: The plot thickensAnastasios Lymperopoulos, Ava Brill, Katie A McCrink
Current Molecular Pharmacology|July 16, 2011
GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic TargetingAlicia N Harvey, Kristy Nguyen, Anastasios Lymperopoulos
Drug Design, Development and Therapy|October 22, 2013
Current and future G protein-coupled receptor signaling targets for heart failure therapyAshley Siryk-Bathgate, Samalia Dabul, Anastasios Lymperopoulos
Journal of Neurochemistry|October 23, 2018
Role of βarrestin1 in AT<sub>1</sub> R-mediated mitogen-activated protein kinase activation in Wistar and SHR brainstem astrocytesShmuel Negussie, Anastasios Lymperopoulos, Michelle A Clark
Pageof 11

Showing results (21-30 of 107) with videos related to

Sort By:
Pageof 11
Pharmacogenomics|December 11, 2014
Pharmacogenetics of cardiac inotropyAnastasios Lymperopoulos, Dilayda Garcia, Karlee Walklett
World Journal of Cardiology|September 29, 2015
Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failureKatie A McCrink, Ava Brill, Anastasios Lymperopoulos
Pharmacology Research & Perspectives|June 26, 2019
Adrenal βarrestin1 targeting for tobacco-associated cardiac dysfunction treatment: Aldosterone production as the mechanistic linkMaria E Solesio, Erna Mitaishvili, Anastasios Lymperopoulos
Circulation Research|August 31, 2013
Adrenergic nervous system in heart failure: pathophysiology and therapyAnastasios Lymperopoulos, Giuseppe Rengo, Walter J Koch
Current Pharmaceutical Design|January 11, 2012
GRK2 inhibition in heart failure: something old, something newAnastasios Lymperopoulos, Giuseppe Rengo, Walter J Koch
Current Drug Metabolism|November 6, 2015
Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and MetoprololAnastasios Lymperopoulos, Katie A McCrink, Ava Brill
The International Journal of Biochemistry & Cell Biology|February 7, 2016
GPCRs of adrenal chromaffin cells & catecholamines: The plot thickensAnastasios Lymperopoulos, Ava Brill, Katie A McCrink
Current Molecular Pharmacology|July 16, 2011
GRK2 and Beta-Arrestins in Cardiovascular Disease: Established and Emerging Possibilities for Therapeutic TargetingAlicia N Harvey, Kristy Nguyen, Anastasios Lymperopoulos
Drug Design, Development and Therapy|October 22, 2013
Current and future G protein-coupled receptor signaling targets for heart failure therapyAshley Siryk-Bathgate, Samalia Dabul, Anastasios Lymperopoulos
Journal of Neurochemistry|October 23, 2018
Role of βarrestin1 in AT<sub>1</sub> R-mediated mitogen-activated protein kinase activation in Wistar and SHR brainstem astrocytesShmuel Negussie, Anastasios Lymperopoulos, Michelle A Clark
Pageof 11